Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing

Top venture syndicate invests to advance expanding pipeline of products to

treat ophthalmic diseases

PARIS, Dec. 12 /PRNewswire/ -- Fovea Pharmaceuticals SA, a biopharmaceutical company developing novel therapeutics for the treatment of ophthalmic diseases announced today that it raised EUR30M ($44M) in a Series B financing from a strong, international syndicate of new and existing investors led by Forbion Capital Partners (Naarden, The Netherlands). All existing institutional investors participated in the round including Sofinnova Partners, Abingworth, GIMV, The Wellcome Trust and CAPE.

Fovea plans to use the proceeds from this financing to advance its clinical and preclinical pipeline and further develop its technology platform. In 2008, Fovea expects to advance its FOV1101 program for chronic allergic conjunctivitis into phase 2 clinical trials and to initiate phase 2 studies of its FOV2302 and FOV2301 programs for the treatment of respectively acute and diabetic macular edema. The company expects to bring its fourth drug candidate, FOV2501, a protein discovered by Pr Jose-Alain Sahel's team (Inserm-UPMC U 592), into clinical trials in the first half of 2009.

"We are pleased that these leading investment firms recognize the value of Fovea's well balanced pipeline and unparalleled expertise in developing these novel therapies," said Bernard GILLY, Ph.D., Chairman and Chief Executive Officer of Fovea Pharmaceuticals. "The company has made enormous progress and this financing will enable us to continue to advance our lead programs through later-stage clinical studies."

"Forbion Capital Partners invests in biopharmaceutical companies pursuing first or best in class drugs. In particular, we focus on companies with strong domain expertise and experienced management. Fovea in our view is well positioned to become a leader in the ophthalmology field. We are impressed by how quickly they have built a highly promising pipeline of products, which will be validated in the clinic using the proceeds of this financing round," said Sander Slootweg, managing partner at Forbion Capital Partners. "We are delighted to invest in Fovea Pharmaceuticals and join an experienced and proven management team along with a very strong and committed group of investors."

In connection with the financing, Sander Slootweg will join the Board of Directors which is comprised of Antoine Papiernik (Sofinnova Partners), Tim Haines (Abingworth), Anthony Wild (Bows Pharmaceuticals) and Bernard Gilly. Bernard Gilly has been elected as Chairman of the Board.

"Fovea's unique product platform has led to the generation of a robust pipeline of promising therapeutic candidates for the treatment of front and back of the eye disorders. Clinical candidates are already in development and at least three new products are expected to progress into the clinic in 2008," commented Pr. Jose-Alain Sahel, Founder of Fovea Pharmaceuticals and Chairman of the Scientific Advisory Board. "It has been a pleasure to work with the talented and productive team at Fovea, and we all look forward to continued progress in exploiting the potential of these novel dedicated therapies."

In parallel to these clinical developments, a strong discovery platform has been implemented, leading to the identification of novel targets. Fovea Pharmaceuticals has recently signed a Research Partnership Agreement with Genzyme to develop gene related therapies on the basis of one of these programs, using Fovea's selected targets to treat major retinal dystrophies.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Created in May 2005, Fovea has a highly experienced board and management team. Fovea has been funded by six leading European investors including Forbion Capital Partners, Sofinnova Partners, Abingworth Management, The Wellcome Trust, GIMV and Credit Agricole Private Equity.

FOVEA has built a project portfolio including internal research programs on dry AMD, glaucoma (neuroprotection), retinal dystrophies as well as clinical programs underway for such indications as macular edema, allergic conjunctivitis, or retinitis pigmentosa.

To advance the development and commercialization of its programs, FOVEA is working both independently and through collaborators including industrial partners like Novartis, Genzyme, CombinatoRx, as well as with academic teams, like the Inserm unit U592, the Rothschild Ophthalmological Foundation, or the Johns Hopkins University.

For additional information about FOVEA and its programs, please visit

About Forbion Capital Partners

Forbion Capital Partners invests in EU and US Life Sciences companies, developing world-class products and technologies. The Forbion team has invested in 38 drug development and med tech companies since 2000, initially as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December of 2006 the group became independent by broadening its investor base and changing its name to Forbion Capital Partners. In recent years, the Forbion team has successfully divested from 13 portfolio companies leaving an active portfolio of 25 companies. Assets under management currently exceed EUR200 M.

Fovea Pharmaceuticals SA

Bernard Davitian

Chief Financial Officer


Press Contacts :

France U.S.

EuroRSCG C&O Russo Partners, LLC

Marie Carole de Groc Wendy Lau

+33158479507 +1-212-845-4272

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... 2015  The ALS Association, in partnership with Prize4Life, ... to revolutionize communication technology solutions for people living with ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease ... the spinal cord. Eventually, people with ALS lose the ... leads to total paralysis and death within two to ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: ... develop and commercialize intellectual property rights belonging to The University of British Columbia ... affords exclusive worldwide rights to intellectual property based on use of the ProMIS™ ...
(Date:10/7/2015)... ... October 07, 2015 , ... The Riordan-McKenna Institute ( ... educational seminar on the latest advances in adult stem cell therapy for orthopedic ... pm at the Hilton Dallas/Southlake Town Square in Southlake, Texas. , RMI offers ...
Breaking Biology Technology:
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ) focused on bringing the life saving ... said today that Matthew Schissler, founder and CEO, in ... Company is very close to becoming cash flow positive.The ...
... CRY ), a biomaterials, medical device and tissue processing company, ... results will be released on Thursday, February 19, 2009. ... at 10:00 a.m. Eastern Time, February 19, 2009, to discuss ... by Steven G. Anderson, president and CEO of CryoLife, Inc.To ...
... INCHEON, South Korea, Feb. 5 The Centers for ... Korean,biopharmaceutical company, have signed a Letter of Intent to ... protect people exposed to,the rabies virus. , ... rabies is a two-step procedure.,First, rabies immune globulin (RIG) ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
Breaking Biology News(10 mins):
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:
... preparation of the catalytic subunit of bovine ... isolated from the yeast Pichia pastoris to ... It recognizes the sequence Asp-Asp-Asp-Asp-Lys and cleaves ... The enzyme can be used to cleave ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Biology Products: